RxDoctor Payments Data

Omasiel Comrie-Reinert

Psychiatric/Mental Health · Lancaster, PANPI 1649721713

Payments from drug & device makers

$5,491in general payments, 2019–2025

Across 82 payments — averaging $66.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$931
  • Otsuka America Pharmaceutical, Inc.$881
  • AbbVie$688
  • Teva Pharmaceuticals USA, Inc.$635
  • Axsome Therapeutics, Inc.$449
  • Alkermes, Inc.$442
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$5,471100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,491 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,218
Medicare patients
30
Services billed
310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$67,051
CaplytaLumateperone Tosylate35$62,421
Abilify MaintenaAripiprazole11$32,035
Invega SustennaPaliperidone Palmitate12$28,657
Lurasidone Hcl30$2,913
Fluoxetine Hcl141$2,847
Hydroxyzine Pamoate88$2,060
Olanzapine35$1,195
Trazodone Hcl122$960
Hydroxyzine Hcl54$943
Aripiprazole28$890
Quetiapine Fumarate113$861
Mirtazapine59$829
Prazosin Hcl61$823
Buspirone Hcl62$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$688$67,05148 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$931$62,42135 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$881$32,03511 claims
Johnson & JohnsonInvega Sustenna$265$28,65712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →